Cargando…

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study

BACKGROUND: Graves’ orbitopathy (GO) is an autoimmune disorder affecting the orbital fat and muscles. A significant role of IL-6 in the pathogenesis of GO has been described and tocilizumab (TCZ), an IL-6 inhibitor targeting IL-6R has been given in some patients. The aim of our case study was to eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boutzios, Georgios, Chatzi, Sofia, Goules, Andreas V., Mina, Areti, Charonis, George C., Vlachoyiannopoulos, Panayiotis G., Tzioufas, Athanasios G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327634/ https://www.ncbi.nlm.nih.gov/pubmed/37424868 http://dx.doi.org/10.3389/fendo.2023.1186105

Ejemplares similares

Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies
por: Boutzios, Georgios, et al.
Publicado: (2022)

Long‐term outcomes in corticosteroid‐refractory Graves' orbitopathy treated with tocilizumab
por: Moi, Laura, et al.
Publicado: (2021)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Occurrence and Antigenic Specificity of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) in Systemic Autoimmune Diseases
por: Argyropoulou, Ourania D., et al.
Publicado: (2021)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
por: Villagelin, Danilo, et al.
Publicado: (2019)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

Late and booster anti‐SARS‐CoV‐2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by XXX et al
por: Bakasis, Athanasios‐Dimitrios, et al.
Publicado: (2022)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications
por: Urselli, Francesca, et al.
Publicado: (2019)

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy
por: Russell, David J., et al.
Publicado: (2017)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2020)

Immunological Features of Paranasal Sinus Mucosa in Patients with Graves’ Orbitopathy
por: Lu, Yi, et al.
Publicado: (2021)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

A case of Tocilizumab-induced thrombocytopenia in steroid-resistant Graves orbitopathy
por: Cuculescu, Victoria, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
por: Wagner, Lilly H., et al.
Publicado: (2022)

High IgG4 serum concentration is associated with active Graves orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2023)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET
por: Ochmann, Anna, et al.
Publicado: (2023)

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy
por: Bartalena, Luigi
Publicado: (2022)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020)

Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients
por: Sánchez-Bilbao, Lara, et al.
Publicado: (2020)

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves’ Orbitopathy: A Pilot Study
por: Rymuza, Joanna, et al.
Publicado: (2022)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
por: Oeverhaus, Michael, et al.
Publicado: (2023)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r88qgfr6hh2b6b2a1kttd163nq